Connect with us

Hi, what are you looking for?

Latest News

RFK Jr’s HHS to end routine COVID vaccine guidance for children, pregnant women: report

The Trump administration is backing away from the Centers for Disease Control and Prevention (CDC) recommendations to vaccinate children and pregnant women against COVID-19, according to a new report.

The Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., is planning to pull federal recommendations that these groups get the COVID vaccine as a routine measure, The Wall Street Journal reported Thursday.

The CDC currently recommends that everyone aged 6 months and older get vaccinated, but that guidance may be scrapped in the coming days.

It’s unclear whether HHS plans to drop the recommendation entirely or simply stop pushing it for everyone across the board, the report said.

The move would be a major shift in federal health policy and would mark a break from the blanket-vaccine approach that dominated the early years of the pandemic.

Few parents and expectant mothers have followed through with recent COVID boosters. As of April, CDC data shows just 13% of children and 14% of pregnant women had received the latest shot.

The change comes as the FDA, under Commissioner Dr. Marty Makary, prepares to roll out a tougher approval process for vaccines. 

Speaking Thursday at a gathering of food and drug lawyers, Makary said, ‘We want to see vaccines that are available for high-risk individuals, and at the same time, we want some good science. We want some good clinical data.’

Kennedy has long been critical of mRNA vaccines and mass vaccination campaigns. As HHS secretary, he now has the authority to revise CDC guidance. 

The Trump administration said it plans to drop routine COVID vaccination guidance for kids and pregnant women, marking a major shift in federal health policy, the WSJ reported.

The expected shift would undercut one of the most promoted health policies of the first Trump administration, Operation Warp Speed, and raise questions about whether insurers will continue covering the shots.

Critics of the move told the Journal it could discourage vaccination and leave immunocompromised people more vulnerable. Supporters say it brings policy back in line with science and common sense.

Both HHS and CDC did not immediately respond to Fox News Digital’s request for comment.

This post appeared first on FOX NEWS

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.







    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Economy

    Stock Market News: UK Forecast and Technical Analysis Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching...

    Investing

    Copper prices are being pushed skyward as China’s stockpiles sit on the verge of depletion and as US demand for the red metal surges,...

    Investing

    Astute Metals NL (ASX: ASE) (“ASE”, “Astute” or “the Company”) is pleased to report assay results from the first of six holes completed as...

    Investing

    Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial Download the PDF here. This post appeared first on investingnews.com

    Disclaimer: Greenlightinvestings.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 Greenlightinvestings.com